|
Squamous cell carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
TTF-1 was expressed in a greater number of ACs (n=20; 95%), with lower mean expression levels, while the corresponding BM expressed the marker less frequently (n=16;76%) with higher mean expression values (p=0.011).P63 was expressed in all SCCs (p=0.68).
|
31646818 |
2020 |
|
Squamous cell carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The p63 positivity and TTF-1 negative expression consequently indicated a poorly differentiated nonkeratinizing SCC, while the opposite immunostaining pattern was flagged in SCLC.
|
31263838 |
2019 |
|
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A total of 1244 NSCLC including 569 squamous cell carcinomas (SqCC) and 675 adenocarcinomas were assembled on a tissue microarray and stained with CK5/6, p40, p63, TTF-1, and Napsin-A.
|
30798982 |
2019 |
|
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The SSP was developed in 68 NSCLC tumors of adenocarcinoma (AC), squamous cell carcinoma (SqCC) and large-cell neuroendocrine carcinoma (LCNEC) histology, based on NanoString expression of 11 (CHGA, SYP, CD56, SFTPG, NAPSA, TTF-1, TP73L, KRT6A, KRT5, KRT40, KRT16) relevant genes for IHC-based NSCLC histology classification.
|
30914778 |
2019 |
|
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
As there are few data from South Africa, we aimed to determine utility of TTF-1, napsin A, p63 and CK5 immunostaining on fine needle aspiration (FNA) cell block and formalin-fixed paraffin-embedded tissue biopsy specimens in subtyping NSCLC as adenocarcinoma and squamous cell carcinomas.
|
31206846 |
2019 |
|
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Immunohistochemical staining against thyroid transcription factor 1 (TTF-1) is often used to distinguish lung adenocarcinoma from squamous cell carcinoma and pulmonary metastasis.
|
30169783 |
2018 |
|
Squamous cell carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Thyroid transcription factor-1 (TTF-1) is overexpressed in up to 95% of primary lung adenocarcinoma while negative for almost all squamous cell carcinomas.
|
30519330 |
2018 |
|
Squamous cell carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Here, we assessed TTF1 CNAs and protein expression using microarrays in a cohort of 636 NSCLC, including 423 adenocarcinoma (ADC) and 171 squamous cell carcinoma (SCC).
|
28378892 |
2017 |
|
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A bronchial biopsy revealed a squamous cell carcinoma p63 positive and TTF-1 negative.
|
28538407 |
2017 |
|
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we reveal that S100A7 overexpression facilitates the transdifferentiation from adenocarcinoma (ADC) to squamous carcinoma (SCC) in several lung cancer cells, which is confirmed by an increase in DNp63 expression and a decrease in thyroid transcription factor 1 (TTF1) and aspartic proteinase napsin (napsin A) expression.
|
28177901 |
2017 |
|
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We identified DSG3 (desmoglein 3), KRT5 (keratin 5), KRT6A (keratin 6A), KRT6B (keratin 6B), NKX2-1 (NK2 homeobox 1), SFTA2 (surfactant associated 2), SFTA3 (surfactant associated 3), and TMC5 (transmembrane channel-like 5) as potential biomarkers for distinguishing between LADC and LSCC.
|
29069744 |
2017 |
|
Squamous cell carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
With addition of IHC (p40 and TTF-1), the latter category reduced to 14.4 per cent and a sum of 225 (85.5%) cases were accurately subtyped into squamous cell carcinoma, adenocarcinoma and adenosquamous carcinoma. p40 showed 100 per cent sensitivity and specificity for squamous differentiation whereas TTF-1 showed sensitivity of 85.3 per cent and specificity of 98.1 per cent.
|
29168459 |
2017 |
|
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To improve segregation between ADC and SqCC in small samples, the classification of lung cancer was updated in 2011, adding immunohistochemistry (IHC) for p63 and TTF-1 to the diagnostic algorithm.
|
25982011 |
2015 |
|
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cell differentiation lineages were unveiled by using thyroid transcription factor-1 (TTF1) for adenocarcinoma (ADC) and p40 for squamous cell carcinoma (SQC), dichotomizing immunohistochemistry (IHC) results for TTF1 as negative or positive (whatever its extent) and for p40 as negative, positive, or focal (if <10% of reactive tumor cells).
|
26317919 |
2015 |
|
Squamous cell carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The present study suggested that the combination of MUC5B and TTF-1 expression is useful for discriminating adenocarcinomas from squamous cell carcinomas, yielding prognostic significance in patients with lung adenocarcinoma.
|
25733373 |
2015 |
|
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We therefore analyzed 102 large-cell carcinomas by immunohistochemistry for TTF-1 and ΔNp63/p40 as classifiers for adenocarcinoma and squamous cell carcinoma, respectively, and correlated the resulting subtypes with nine therapeutically relevant genetic alterations characteristic of adenocarcinoma (EGFR, KRAS, BRAF, MAP2K1/MEK1, NRAS, ERBB2/HER2 mutations and ALK rearrangements) or more common in squamous cell carcinoma (PIK3CA and AKT1 mutations).
|
23196793 |
2013 |
|
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Diagnostic combinations were p40-/TTF1+ or TTF1- for AD (where p40 was negative, apart from 5/30 AD showing at the best 1-2% tumor cells with low intensity); p40+/TTF1- (p40 strong and by far higher than 50%) for SQC; and p40+/TTF1+ or p40+/TTF1- (p40 strong and less than 50%) for ADSQC.
|
22071786 |
2012 |
|
Squamous cell carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
For brain metastases, FOXA1 expression was slightly higher in the SCC samples (55.6%) compared with the non-matched primary SCC tumor samples (43.4%), whereas NKX2-1 expression was comparable in both primary tumors and brain metastases.
|
22383183 |
2012 |
|
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ninety-five resected SQCCs, verified by immunohistochemistry as ΔNp63(+)/TTF-1(-), were tested for activating mutations in EGFR, KRAS, BRAF, PIK3CA, NRAS, AKT1, ERBB2/HER2, and MAP2K1/MEK1.
|
22228640 |
2012 |
|
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
TITF-1 copy number gain(CNG) was detected by FISH analysis in both adenocarcinomas (18.9%; high CNG, 8.3%) and SCCs (20.1%; high CNG, 3.0%), and correlated significantly with the protein product (P = 0.004) and presence of KRAS mutations (P = 0.008) in lung adenocarcinomas.
|
21257719 |
2011 |
|
Squamous cell carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In subclasses, the expression rate of TTF-1 mRNA was obviously higher in PEs of patients with PPA (93.0%) than with metastatic pulmonary adenocarcinoma (0%) and with primary pulmonary squamous cell carcinoma (12.5%).
|
18855882 |
2008 |
|
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
TTF-1 was detectable in 4/99 (4%) squamous cell carcinomas, 169/176 (96%) solitary adenocarcinomas, 34/34 (100%) multifocal adenocarcinomas, 1/1 (100%) signet ring cell carcinoma, 16/20 (80%) mucinous adenocarcinomas, 23/23 (100%) nonmucinous bronchioloalveolar carcinomas, 19/36 (53%) small cell carcinomas, and 39/44 (89%) sclerosing hemangioma.
|
15084379 |
2004 |
|
Squamous cell carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
TTF-1 expression was seen in 45.6% of all tumors (80% of ADs and 14% of squamous cell carcinomas).
|
12051626 |
2002 |
|
Squamous cell carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
By reverse transcription polymerase chain reaction, expression of thyroid transcription factor-1 messenger RNA was observed in squamous cell carcinomas in addition to in adenocarcinomas and small cell lung carcinomas, and this finding was confirmed in the cell lines from squamous cell carcinomas.
|
12379752 |
2002 |